Friday, 31 July 2009

Ropinirole Hydrochloride (Ran-Ropinirole) 0.25 mg, 1.0 mg, 2.0 mg, and 5.0 mg tablets: Ranbaxy got “Notice of Compliance” to market in Canada

Indian pharma giant Ranbaxy Pharmaceuticals Canada Inc announced that RLL has received approval in Canada to manufacture and market Ran-Ropinirole 0.25 mg, 1.0 mg, 2.0 mg, and 5.0 mg tablets (Ropinirole Hydrochloride) from Health Canada, Therapeutic Products Directorate (TPD). Total generic market size of Ropinirole Hydrochloride tablets in Canada is $4.8 million ($CAD) [IMS-CDH: July 2008]. Ran-Ropinirole tablets are indicated for use as an anti-parkinsonian agent and dopamine agonist.

Posted by ADKS at 1:35 pm

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)
web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker